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SUMMARY 
Human Cytomegalovirus (CMV) is a beta-herpesvirus that commonly infects humans. 
Most symptoms in healthy individuals are very mild. The virus is never eliminated and 
remains in the individual life-long. Thus, CMV and the immune response stay in 
coexistence until the protective response remains. CMV disease occurs when the immune 
system is either immature or immunocompromised, such as in hematopoietic stem cell 
transplant recipients. Over the last decades, CMV has been reported in diverse cancer 
including glioblastoma (GBM) that could suggest a potential link between CMV infection 
and cancer initiation or development.  
The papers in this thesis investigated the CMV-specific immune response of individuals in 
different clinical settings: patients after hematopoietic stem cell transplantation (HSCT) and 
patients with brain tumor or pancreatic cancer. The thesis consists of the following studies: 
In Paper I, we investigated the CMV-specific interferon-gamma (IFNγ) production in a 
cohort of 277 patients over time post-HSCT. Impairment of the CMV-specific immune 
response post-HSCT is associated with CMV infection. We monitored the IFNγ production 
in response to CMV-pp65 over a period of 2 years post-HSCT and observed a higher IFNγ 
production at the first month post-HSCT. Moreover, we identified that several clinical 
parameters such acute graft-versus-host disease (GVHD) and CMV infection affect the 
IFNγ production in response to CMV-pp65. 
In Paper II, we aimed to characterize the CMV-specific CD8+ cytotoxic T-cells (CTL) 
with high affinity T-cell receptor (TCR) in patients post-HSCT using three different CMV-
pp65 tetramers. High affinity CMV-CTL presented an effector memory phenotype and a 
stronger PD-1 expression as compared to CMV-CTL with lower affinity. Additionally, the 
high affinity CMV-CTLs were found at higher proportion in patients with chronic GVHD 
over time post-HSCT. Therefore, Paper I and II together may better characterize the 
CMV-specific immune response post-HSCT and potentially the bidirectional relationship 
between virus and GVHD.  
In Paper III, we investigated the plasma interleukin 7 (IL-7) and the soluble IL-7 receptor 
(sIL-7R) levels post-HSCT. IL-7, through its receptor, is essential for T-cell proliferation, 
thus, to the response to infection. Patients presenting CMV infection exhibited a lower 
plasma level of sIL-7R and higher level of IL-7 in the early months post-HSCT. 
Furthermore, the plasma level of IL-7R was reduced in patients with acute GVHD. 
Together these observations suggest that sIL-7R may be associated with increased risk of 
GVHD and potential CMV infection. 
In Paper IV, the clinical setting is different. We focused on the CMV-specific IFNγ 
production in a large cohort of patients with brain tumor and pancreatic cancer. Patients 
with brain tumor and more specifically those with GBM presented an impaired immune 
response towards viral and mitogen antigens. While survival was correlated with the CMV-
specific humoral response, no correlation between survival and CMV-specific IFNγ 
production could be observed. Contrarily, patients with high Epstein-Barr virus (EBV)- and 
PHA-specific IFNγ production showed an improved survival post-operation suggesting this 
immune response as potential marker of general immunocompetence. 
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A astrocytoma 
aa amino acid 
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HHV Human herpesvirus 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HSCT hematopoietic stem cell transplantation 
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IFN-γ interferon gamma 
Ig immunoglobulin 
  
IL- interleukin- 
L late 
M metastasis 
MAC myeloablative conditioning 
MHC major histocompatibility complex 
MMF mycophenolate mofetil 
MUD matched unfamiliar donor 
NK natural killer cell 
OA/O oligoastrocytoma /oligodendroglioma 
Pan Can pancreatic cancer 
PBMC peripheral blood mononuclear cells 
PCR polymerase chain reaction 
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Pp65 phosphoprotein 65 
PTLD post-transplant lymphoproliferative disease 
RIC reduced intensity conditioning 
Sib sibling 
TCM central memory T-cell (CD45RA- CCR7+) 
TCR T-cell receptor 
TEM effector memory T-cell (CD45RA- CCR7-) 
TEMRA terminally differentiated T-cell (CD45RA+ CCR7-) 
TGF-β Transforming growth factor beta 
TNF-α tumor necrosis factor alpha 
Treg regulatory T-cell 
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1 INTRODUCTION 
 
1.1 HUMAN CYTOMEGALOVIRUS 
 
1.1.1 Overview 
While the thesis is focused on the specific immune response to CMV, it is important to 
briefly describe the virus itself and its biology to better understand the clinical implication of 
the pathogens and, therefore, the necessity to continue the research on such a common, 
“inoffensive” virus. 
Inclusion bodies in the nucleus, characteristic of human Cytomegalovirus (CMV) infection, 
were first observed in the late nineteenth century and then described in 1939 in lethal 
congenital cases (CID, called generalized cytomegalic inclusion disease). It was successfully 
isolated for the first time a decade later by three independent laboratories: Rowe, Smith, and 
Weller 1. CMV infection, unnoticed in healthy individuals, infects a large proportion of the 
world’s population 2, with a seropositivity ranging from 30% to 100% in adults depending on 
age, country, population density, and socioeconomic status 3. Primary and persistent CMV 
infections are controlled by acquired immunity in healthy individuals and can be revealed by 
the presence of circulating antibodies specific against CMV. Both humoral and cellular 
immunity are involved in protective immune responses to CMV reactivation and CMV 
resolution 4. CMV disease occurs in situation where the immune system is either immature or 
immunocompromised such as fetuses, HIV-positive patients, and recipients of solid organ or 
hematopoietic stem cell transplants. Over the last decades, association of human CMV in 
diverse cancer such as prostate cancer, colon cancer, or brain cancer has been reported 
suggesting a potential link between CMV infection and cancer initiation or development 5-8.  
 
1.1.2 Biology 
Human CMV is a member of the human herpesvirus family that includes also Epstein-Barr 
virus (EBV), varicella-zoster virus, herpes simplex virus 1 and 2, HHV-6 A and B, HHV-7, 
and HHV-8. It belongs to the β-herpesviridae subfamily and is also known as human 
herpesvirus 5 (HHV-5). Its genome of 235 kilobase pair, double-stranded DNA, contains 165 
genes9. More than 200 open reading frames (ORF) encode over 200 proteins in three 
overlapping phases (immediate early (IE), early and late) and 50 ORFs are involved in viral 
replication and immune evasion 10. The structure of the virion is similar to the other 
herpesviruses consisting of an extern lipoprotein envelope containing an icosahedral capsid 
(162 capsomers) formed by major and minor proteins. The envelope is composed of 
glycoproteins such as gB, gN, gO, gH, gM, and gL. The tegument, a layer between the 
envelope and the capsid, contains immunogenic proteins of which pp65 was the antigen used 
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in the so called antigenemia assay for monitoring CMV infection due to its abundance. 
Tegument proteins are important for viral gene expression, maturation of the virus and 
initiation of infection 11. The capsid carries the genome which is single, linear double-
stranded DNA 12. 
 
1.1.3 CMV Infection 
The infection can be acquired by different routes: i) Congenital infection, which is a vertical 
infection from the mother to the fetus during pregnancy. Congenital CMV infection may 
cause neurological damage such as sensorineural hearing loss, neurodevelopment disability, 
fetal or neonatal death in 10-20% of congenitally-infected children. The risk for mortality and 
severe sequalae is highest in primary infection of the pregnant woman. Intrauterine infection 
has a prevalence of 0.2% to 2.5% differing between countries 13; ii) Perinatal infection is 
acquired during delivery from infected maternal cervix; iii) Postnatal infection can be 
obtained by breast feeding (milk). Another route is through viral excretion in saliva and 
transmission can most probably occur at an early-age from child-to-child in child care centers 
and playgrounds 14. Occasionally, cases of CMV mononucleosis “kissing disease” (similar to 
EBV mononucleosis) are observed in young adults, representing 8% of all cases of infectious 
mononucleosis 15. iv) CMV infection via blood transfusion was first observed during the 
1960s. Nowadays, it is an uncommon event considering the progress in donor screening 
(CMV seronegative) and the use of leukoreducted blood products 16,17. v) Human CMV is a 
significant pathogen in solid organ transplantation and symptoms are more severe in the 
seronegative recipient (R-) of an organ from a seropositive donor (D+). Thus, the patient 
experiences a primary infection and 60%-80% of R-D+ patients develop a CMV infection 
18,19. CMV’s role in HSCT is outlined in detail below. 
 
1.1.4 CMV Pathogenesis 
Human CMV pathogenesis is complex due to a tight conflictual relation with the immune 
system and a broad range of target cells. The cell tropism for CMV varies among strains and 
explains the numerous different clinical presentations of CMV disease 20. CMV can infect a 
wide range of cells such as endothelial cells, epithelial cells, fibroblasts, smooth muscle cells 
as well blood cells including monocytes, macrophages and neutrophils 20. Monocytes are the 
major blood cell-type infected by CMV during acute infection and can serve as transport 
before the differentiation into macrophages in the tissue where the viral replication occurs 
21,22. Therefore, most virus transmission through blood products can be prevented by removal 
of leukocytes. There is also evidence that supports the role of endothelial cells in viral 
dissemination and complete replication cycle 23. To facilitate viral dissemination, the virus 
encodes chemokines to attract monocytes and neutrophils but the molecular mechanism 
remains unknown 24. CMV might be found in bone marrow CD34+ cells and in all the organs 
in case of severe disseminated disease 25. 
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As mentioned earlier, studies have shown at least indirect involvement of CMV in several 
cancers but it has also been suggested that there is a correlation with various inflammatory 
diseases like atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis 26-30. 
 
1.2 THE ADAPTIVE IMMUNE SYSTEM 
 
This thesis focuses mainly on the T-cell immune response toward CMV, but the immune 
system is a large, well-tuned network that provides defense against disease. Therefore, it is 
necessary to briefly introduce the different type of immune functions. The first line of defense 
against CMV is the innate immunity. Natural killer (NK) cells appear to be major players in 
early CMV control 31. Innate immunity provides immediate response against infection and 
helps to initiate other immune responses through production of cytokines and expression of 
co-stimulatory molecules. Historically, NK cells were described to not being able to generate 
immunological memory like adaptive immune response but this idea was challenged recently 
as NK cells can acquire long-lasting and antigen-specific memory 32,33. The adaptive immune 
system, by engaging both humoral (antibody production) and cellular (T- and B- 
lymphocytes) immunity, greatly improves the defense and specificity against a distinct 
pathogen such as CMV. 
The adaptive immune system consists mainly of the B- and T- lymphocytes. Naïve B-cells 
migrate from the bone marrow (central lymphoid organ) to the germinal center of peripheral 
lymphoid tissues, such as lymph nodes, to complete the maturation process. B-cells 
recognize, bind and internalize specific antigens via the membrane B-cell receptor (BCR) 
which is identical to soluble immunoglobulin (Ig). After internalization and processing of the 
internalized molecules, B-cells present the major histocompatibility complex (MHC) class II 
– antigen on their surface. This allows the interaction with CD4+ T-cells to finalize the B-cell 
development by proliferation and differentiation. B-cells end their development by leaving 
the germinal center to become plasma cells or memory B-cells. Plasma cells are considered 
as effector B cells; they secrete a large volume of different immunoglobulins with variable 
functions: IgG, IgM, IgA, IgD and IgE. These antibodies contribute to antigen-neutralization 
by coating the infecting pathogen. The coating allows two ways to eliminate the pathogens: 
Antibody opsonization resulting in phagocytosis of the pathogen and the complement-
mediated cytolysis of the pathogen. Thus, the humoral response orchestrated by B-cells play a 
major role in the extracellular pathogens and toxins neutralization towards lysis 34.  
 
1.2.1 T-cell mediated immune response 
Similar to B-cells, T-cells first develop in the bone marrow but, instead of migrating directly 
to the peripheral lymphoid tissues, T-cells have an intermediate step in the thymus where 
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education of the T-cell receptor (TCR) and selection of the T-cell repertoire occurs. Initiation 
of the T-cell response takes place in the lymph nodes (peripheral lymphoid tissues) where 
antigen-presenting cells (APC) display the target peptide driving the expansion and the 
differentiation of the antigen-specific T-cells that then migrate to the site of infection. T-cells 
are essential in eradication of intracellular pathogens. 
1.2.1.1 CD4+ T-cells 
CD4+ T-cells work in close collaboration with B-cells necessary for activation, clonal 
expansion and specific immunoglobulin production. Additionally, they are important to 
activate and expand cytotoxic T-cells (CTL) and contribute to macrophage activation; for 
those reasons, CD4+ T-cells are also called helper T-cells. CD4+ T-cells are activated in the 
peripheral lymphoid tissue by the interaction between their TCR and the major 
histocompatibility complex (MHC) II on APC surface, presenting the antigen peptide of a 10-
30 amino acids length. Differentiation of CD4+ T-cells is dependent on the co-stimulatory 
signals between the APC and the T-cells and can lead into four major distinct CD4+ T-cells 
phenotypes: Th1, Th2, Th17 and Treg (regulatory T cell) characterized by their cytokine 
production and transcriptions factors as describe in Figure 1. Th1 cells produce interferon-
gamma (IFNγ), interleukin- (IL-) 2 and lymphotoxin α making them particularly effective 
against intracellular pathogens; Th2 cells produce IL-4, IL-5 and IL-13 for a strong response 
to extracellular pathogens; Th17 cells, by producing IL-17 and IL-21, show ability to respond 
specifically to extracellular fungi and bacterial infections while Tregs, as the name indicates, 
regulate the immune response and provide self-tolerance by the production of IL-10 and 
TGF-β 35. 
More than these four subsets exist and have been described in the past and recently: Thf, Th9, 
Th22 and Th1* but the phenotype of those CD4+ T-cells is not “fixed”, i.e not all terminally 
differentiated and instead present plastic ability 36.  
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Figure 1: CD4+ T-cells subsets 
 
1.2.1.2 CD8+ T-cells 
Together with the IFN-γ producing Th1 cells, CD8+ T-cells are the main immune component 
of this thesis. TCR of the CD8+ T-cells recognize peptide antigens of 8 to 11 amino acid 
length presented by surface MHC II of APC that beforehand internalized the pathogen. 
Activated CD8+ T-cells are also called cytotoxic T-cells (CTL) due to their specific and 
effective response upon activation. Activated CD8+ T-cells present an effective cytotoxic 
activity toward target cells characterized by: i) production of perforin and granzymes 
(especially granzyme B) that disrupt the membrane and induce apoptosis via caspase 
activation of the targets cells; ii) IFN-γ and tumor necrosis factor alpha (TNF-α) production 
(pro-inflammatory cytokines) that contribute to resolution of infection 37.  
1.2.1.3 Memory T-cells 
One of the strong points of the adaptive immune response, in addition to its antigen 
specificity, is its ability to generate long-term memory response. The CD8+ memory T-cell 
can be achieved by the help of the CD4+ T-cells 38. Different markers define a memory T-
cell: CD45RA, CD45RO, CCR7 and CD62L allow the separation of 4 distinct subsets such 
as naïve, central memory (TCM), effector memory (TEM) and terminally differentiated 
effectors (TEMRA) T-cells as described below in Figure 2 39. Briefly, naïve T-cells 
expressing CD45RA, CCR7 and CD62L circulate in the peripheral blood until they encounter 
APC for antigen stimulation. Once activated, CD8+ T-cells loose the CD45RA expression to 
become TCM cells. In general, these cells no longer require co-stimulation for activation, 
produce IL-2 but keep the high proliferative capacity characteristic of stem cell-like 
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proprieties 40. TEM cells express neither CD45RA nor CCR7; therefore they can migrate 
from lymphoid to peripheral tissues to target their specific antigens. Upon encountering 
antigen TEM cells produce IFNγ, TNFα, perforin and granzyme B. TEMRA cells are the 
final subset of the memory T-cell before apoptosis once the infection has been cleared. They 
retrieve the expression of CD45RA and produce a large quantity of perforin and granzyme B 
for optimal cytotoxic activity to pathogens. The proportion of memory subsets differs 
depending on the antigen stimulation. The pathogen seems to shape the memory immune 
response. 
 
Figure 2: CD8+ memory T-cell subsets 
 
1.2.1.4 MHC class I and II 
Class I and class II major histocompatibility molecules (MHC), also called HLA (human 
leukocyte antigen) in humans, are molecules on the cell surface that present peptides to others 
(immune) cells. Displayed peptides can be self- or non-self-antigens. The two classes of 
MHC define two different functions: class I MHC (HLA-A, -B, -C) molecules are present on 
the surface of virtually all nucleated cells while class II MHC (HLA-DR, -DQ, -DP) 
molecules are expressed only on APCs such as dendritic cells, macrophages or B-cells. Class 
I MHC molecules display peptide residue from intracellular pathogens to CD8+ T-cells while 
class II MHC molecules display peptide residue from extracellular pathogens to CD4+ T-
cells (Figure 3). Note that class I and class II MHC molecules are extremely diverse with over 
15,000 MHC alleles that code for specific HLA receptors, making HLA the most 
polymorphic region of the human genome 41. This high genetic diversity may allow humans 
to adapt to environmental challenges playing an important role in immune response.  
1.2.1.5 TCR stimulation and signalization 
As described above, APCs present the bound peptide via their MHC molecules and stimulate 
the T-cells through their TCR. The TCR consists of two transmembrane polypeptide, 
covalently-linked chains α and β. Those unique α and β chains recognize the antigen peptide 
presented by α1 and α2 domains of the class I MHC or α 1 and β1 domains of the class II 
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MHC. Co-receptors CD4 and CD8 augment the TCR signaling and stabilize the MHC-TCR 
interaction, enhancing TCR affinity 42,43. Briefly, the MHC-antigen complex binds the TCR 
and initiates the signal via the CD3 complex. T-cell activation occurs by the intermediate of a 
co-receptor (CD4 or CD8) and co-stimulatory receptor such as CD3 and CD28 (Figure 3). 
Altogether, this leads to an intracellular phosphorylation cascade involving several proteins 
(zeta-chain-associated protein kinase 70 (ZAP-70), lymphocyte-specific protein tyrosine 
kinase (LCK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)) inducing the 
cellular activation characterized by cell proliferation, differentiation, survival and cytokine 
production 44.  
 
Figure 3: Representation of MHC – TCR interaction. 
 
1.2.2 Cytokines 
To orchestrate the most efficient immune defense, signaling between the different immune 
cells is essential. Cytokines are critical against viral infection but also have an in important 
role in cancer. A broken balance in the cytokine production or the network can lead to a life-
threatening situation. Some were previously was mentioned and, in the scope of this thesis, it 
is important now to describe them in more detail. 
1.2.2.1 Interferon gamma 
IFNγ is a major cytokine that enhances the cellular immune response and is essential for host 
defense. IFNγ is produced by Th1 CD4+ T-cells, CD8+ T-cells and NK cells. Its receptor, 
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expressed on many cells 45, is composed of two chains: α chain (IFN-γRI) that plays the 
binding role and chain β (IFN-γRII) responsible for the biological response. Many cells 
express IFNγ receptor but macrophages are the main receptive population, significantly 
enhancing their activation and microbicidal function. Furthermore, IFNγ has an 
immunomodulatory effect on B-cells as it inhibits activation and induces isotype switching to 
IgG2a. This cytokine also drives the CD4+ T-cell differentiation to Th1 while inhibiting the 
proliferation of Th2 cells 46. Importantly, the expression of MHC molecules is upregulated 
and antigen presentation to T-cells increased by IFNγ. Altogether it shows how important 
IFN-γ is against tumors and intracellular pathogens 47.  
1.2.2.2 Interleukin 7 and Interleukin 7 Receptor 
Interleukin-7 (IL-7) is an indispensable cytokine for the development of the immune system. 
IL-7 influences T-cell homeostasis, peripheral T-cell survival, memory induction and B-cell 
development. Therefore, IL-7 improves the immune response during infection but is also 
involved in the severity autoimmune disease due to its proinflammatory propriety, inducing 
production of TNFα 48,49. IL-7 is produced by stromal cells in lymphoid tissues, intestinal 
epithelium, keratinocytes and few other cells. Its receptor IL-7R is expressed on many 
different cells but most importantly on T- and B-cells. Note that its expression varies 
depending on the maturation and lifetime of those immune cells 50. IL-7R is a dimer 
composed of the common γc chain and CD127. γc chain is also a common sub-unit to other 
interleukin receptors: IL-2, IL-4, IL-9, IL-15 and IL-21. The binding of IL-7 to IL-7R results 
in a phosphorylation cascade leading to cell proliferation, survival, differentiation and 
activation. Due to alternative splicing at RNA level, different isoforms of soluble IL-7R (sIL-
7R) have been described 51. The exact function of the different soluble receptor forms is still 
elusive but different hypothesis and research present the soluble isoform as an inhibitor of the 
membrane receptor but it may also play as stabilizer of the cytokine in the extracellular 
environment 52,53 
 
1.3 CMV-SPECIFIC IMMUNE RESPONSES 
 
Immunocompetent individuals can keep CMV suppressed into a latent state, however, the 
immune system cannot achieve a total clearance of the virus. Disturbing the balance between 
the virus and the immune response can lead to CMV replication with a potential CMV 
disease development. CMV-specific immunity includes cellular and humoral responses 
(Figure 4). 
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Figure 4: Innate and adaptive CMV specific immune response, adapted from Adland E et al. 54 
 
1.3.1 Humoral Response against CMV 
Humoral immunity is crucial to restrict viral dissemination by producing neutralizing 
antibodies that block the virus infection 55. 
During primary infection, Immunoglobulin M (IgM) antibodies are produced rapidly and 
persist for 3 to 4 months while IgG antibodies persist life-long. IgM antibodies are often not 
produced during viral reactivation but can occur in some individuals. The production of 
CMV-specific antibodies is maintained through the activation of the B-cells by the CD4+ T-
cells. These antibodies are directed against specific viral glycoproteins such as gB and gH to 
neutralize viral particles and abort the infection but cannot target the CMV-infected cells 56. 
CMV gB antibodies can be detected in all individuals infected by CMV, making gB one of 
the major targets for the antibodies and a promising vaccine candidate since it is a well-
conserved protein and necessary for viral entry 57-59. A study suggested that primary CMV 
infection induces an important functional exhaustion of B lymphocytes that may limit the 
production of antibodies and the control of viral dissemination 60. However, the humoral 
immune response is believed to play a minor role after HSCT 
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1.3.2 T-cell Response against CMV 
Cellular immune response is the predominant and critical immune mechanism that controls 
CMV. Suppression of CMV-specific T-cells can result in reactivation which is why CMV-
disease occurs most commonly in patients with severe, impaired cell-mediated immunity 
such as those with HIV and organ transplants. The median frequency of circulating CMV-
specific memory T-cells in healthy individuals is 10% of the circulating memory T-cells. This 
is considerably higher than the median observed for any other human viruses such as 
influenza, adenovirus or poxvirus, and similar to the HIV-specific T cells in active HIV 
infection 61. CMV-specific memory CD8 T cells are composed by 50% of terminally 
differentiated cells (CD45RA+CCR7-) and 40% of effector cells (CD45RA–CCR7−) 62. The 
specific T-cell frequency necessary to control the virus infection has not been determined. As 
mentioned earlier, pp65 matrix protein is one of the significant targets for the CMV specific 
T-cells (CMV-CTL). The percentage of healthy individuals with CD8 T-cells specific to 
pp65 is around 85% with a high degree of clonality for the protein target. 
However, CMV-CTL responses are diverse containing multiple antigen-specific reactivities 
towards >70% of the CMV ORF. CD8+ T-cells specific to CMV seem to present a different 
profile regarding the virus infection i.e acute/primary (CCR7−CD27+CD45RA−) or chronic 
(CCR7−CD27-CD45RA+) that has been linked to terminal differentiation as well as 
dysfunction, defined by the re-expression of CD45RA 63,64. 
Less is known about CD4+ T-cells responses after primary CMV infection. In young children 
infected in utero, CMV-specific CD4+ T-cell responses are very low but can rapidly expand 
after primary infection in adults 65. ORF recognition pattern of CMV-specific CD4+ T-cells 
overlaps with the CMV-specific CD8+ T cells and as for the CD8+ T cells, responds to a 
large number of antigens 61. Most healthy individuals have CMV-specific CD4+ T-cells 
directed against gB and pp65 antigens and seem to have a preferential recognition for 
immediate early (IE) genes. CD4+ T cell are mostly described as helper T cells, but a CMV-
specific CD4+ T cell subset (CD28- and mainly CCR7-) associated with chronical viral 
infection shows some cytotoxic proprieties by producing high levels of anti-viral cytokines 
such as IFNγ and TNFα 66,67.  
Primary CMV infection with an intense viral replication is associated with reduced CD4+ T-
cell proliferation, increased PD-1 expression and defective IL-2 production whereas 
acquisition of CD4+ T cell proliferative response against CMV is associated with viremia 
control 68. Interestingly, CMV-specific CD4+ T cell responses occurred earlier than CMV-
CTL responses in asymptomatic individuals but were delayed in symptomatic individuals. 
The CMV-specific CD4+ T cell response was observable again after antiviral treatment 
suggesting that IFNγ–secreting CD4+ T cells are indispensable for CMV-protective 
immunity 69. 
CMV-CTLs are dominant and persist at high frequency in peripheral blood after primary 
infection. This is in contrast to the CMV-specific CD4+ T-cells that decline rapidly following 
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an initial peak. During persistent/chronic infection, CMV-specific CD4+ T-cells appear to be 
more dominant to maintain an efficient CMV-specific immunity through cytokine production 
and by supporting antibody production 69-71. 
 
1.3.3 T-cell Inflation 
With aging, the T-cell population changes so that the naive population frequency decreases 
while there is an accumulation of differentiated T cells 72. In addition to the immune 
senescence associated with aging, this may contribute to a survival decrease in the elderly due 
to infections.  CMV is one of the major driving forces involved 73-75. In an elderly population, 
the accumulation of CMV-CTL populations increase the number of dysfunctional CD8 T-
cells characterized by their oligoclonal/monoclonal inflation 76,77. This “memory T-cell 
inflation” towards CMV is associated with impaired immunity by narrowing the CD8 T-cell 
repertoire, constricting the immunological space for other antigens 78. 
 
1.3.4 CMV Immune Evasion 
CMV is a paradigm for viral immune evasion through its ability to utilize a multitude of 
immune modulatory strategies. Multiple genes are involved in viral immune evasion, 
interfering adaptive and innate immune response at every phase of the CMV life cycle 
allowing the virus to establish latency with lifelong shedding. 
Briefly, CMV interferes by affecting the interferon-mediated immunity (induced early during 
infection) but also by encoding cmvIL-10. This cytokine homolog downregulates the 
production of IFNγ and TNFα and the expression of both class I and II MHC 79. CMV is also 
able to prevent apoptosis to promote survival and to interfere with the T cell immune 
response to infection by restricting the presentation of viral antigen by both MHC class I and 
II molecules during every infection phase (reviewed in Table 1). 
Infection Phase  Function 
Intermediate Early US3 Retains MHC I molecules in the ER, reduces MHC II presentation 
Early 
miR-US4-1 Suppresses translation of ERAP1 to limit loading of antigenic peptides 
US2 Induces degradation of MHC class I molecules 
US10 Retains MHC class I heavy chains, induces degradation of HLA-G 
US11 Induces degradation of MHC class I molecules 
Early / Late UL82 (pp71) 
Delays progress of MHC class I complexes from the 
ER to the Golgi 
UL83 (pp65) Prevents generation of viral antigenic peptides 
Late US6 Inhibits the translocation of peptides by the TAP complex 
Table 1. CMV modulation of the T-cell immunity by interference of MHC class I and class II 80. 
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1.4 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
1.4.1 Overview 
The first HSCT was performed mid-twentieth century as a salvage against the lethal effects of 
radiation. Today HSCT provides an effective curative treatment against many diseases such 
as hematologic malignancies, severe combine immunodeficiencies, autoimmune disorders, 
and some inherited metabolic diseases. Different sources of stem cells are used: bone 
marrow, umbilical cord blood and peripheral blood stem cells 81. Many parameters are 
essential to consider when performing a HSCT procedure such as the patient and donor age, 
the donor/recipient HLA match, and the general condition of the patient. As the procedure 
remains associated with morbidity and mortality, HSCT is used mainly for patients with life-
threatening diseases. After HSCT, the major complications, besides relapse of the underlying 
disease, are infections and graft-versus-host disease (GVHD). Those complications can be 
influenced by the donor selection (sibling vs. unrelated, HLA-match vs. mismatch) and the 
conditioning of the patient before the transplant. Conditioning regimen varies significantly 
from myeloablative (MAC) to reduced-intensity (RIC) conditioning and are needed to 
eradicate the disease (malignant cells for example) and eliminate/suppress the recipient 
immune function to allow the engraftment of the donor cells.  
The early period after HSCT is commonly characterized by an aplastic phase due to the 
conditioning regimen aimed to suppress/eradicate the immune system. The risks during this 
period are influenced by the intensity of the conditioning regimen. During this period there is 
a high risk of bacterial and fungal infections which remains until neutrophils and 
granulocytes recover at approximately 2 to 4 weeks after transplantation depending of the 
stem cell source.  
Graft-versus-host disease is a common and severe complication after HSCT, consequence of 
an attack by the donor cells against the patient tissues. Acute GVHD (aGVHD) remains a 
major cause of morbidity and mortality post-HSCT and affected organs are skin, liver and 
gastrointestinal tract 82. Acute GVHD occurs within the first 100 days post-HSCT and is 
classified into four grades (I to IV) depending on the severity and involved organs. Acute 
GVHD pathogenesis goes through a three-phase evolution and was first described by 
Billingham already in 1966 83. First, the afferent phase is a consequence of the conditioning 
regimen characterized by damage to the host tissue which creates an inflammatory response. 
The excessive release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α 
upregulates MHC expression on the APCs. Donor T-cells can then recognize the activated 
host APCs presenting host antigens leading to an alloimmune response and a cytokine storm. 
Pro-inflammatory cytokines induce the efferent phase of aGVHD which is the trafficking and 
expansion of more effector immune cells. Activated donor T-cells produce IL-2 (and IFN-γ 
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but its role is not well understood) that amplify the allogenic immune response. T-cells and 
NK cells induce the release of TNF-α by macrophages that damages the different organs 
(skin, gut, liver). Last, the effector phase that leads to the clinical manifestation of aGVHD: a 
cascade of cellular and inflammatory effects where activated donor T-cells, maintained by 
Th1 cells, mediate cytotoxic damage by production of perforin and granzyme and release of 
more TNF-α, further stimulating the “cytokine storm” effect. Altogether, this dysregulation 
causes end-organ damage and a continual loop of events involving neutrophils, NK cells and 
macrophages 84. Increasing evidence supports that the microbiome composition is important 
for the development of aGVHD especially in the gut. Chronic GVHD (cGVHD) occurs later 
after the transplant and is the main factor affecting the long-term quality of life after HSCT. 
In most cases, cGVHD is preceded by aGVHD and the symptoms affect the skin, liver and 
oral mucosa. Chronic GVHD can be classified into mild, moderate and severe grades 
depending on organ manifestations and the number of organs affected. 
To prevent GVHD, patients are usually given a combination of prophylactic 
immunosuppressive agents such as calcineurin inhibitors (cyclosporine or tacrolimus) with 
the addition of methotrexate, corticosteroids, or mycophenolate mofetil (MMF) 85. Therefore, 
the challenge for the clinicians is to treat GVHD without diminishing the graft-versus-tumor 
(GVT) effect of the HSCT or increasing the risk of infections. Treatments of established 
GVHD vary depending on the severity of GVHD: from topical corticosteroids for grade I 
aGVHD to systemic corticosteroids with or without additional therapies for more severe 
grades mainly targeting T-cells. The treatment of chronic GVHD is more challenging as 
patients need immunosuppressive treatment for a long period of time but first line therapy 
remains a combination of calcineurin inhibitors and corticosteroids. Many second line 
therapies are being tested targeting either T-cells or B-cells. 
 
1.4.2 T- and B- cell Reconstitution post-HSCT 
Reconstitution of the innate immunity is faster (within weeks) than the adaptive immunity 
(within months to years): Natural Killer (NK) cells, monocytes, granulocytes and dendritic 
cells (DCs) are restored rapidly following HSCT, whereas B-cells and T-cells frequently 
show delayed and incomplete recovery 86,87. Long-term immune reconstitution post-HSCT is 
influenced by several factors such as the conditioning regimen, T-cell depleting agents, the 
source of stem cell, but also by clinical events such as GVHD, infections and relapse 88. 
The first months after HSCT are characterized by a cellular immune deficiency with a lack of 
cytotoxic T-cells/poor cytotoxic T-cell function. Memory T-cells are the first to expand, 
driven by cytokines and the presence of alloreactive antigens; they can be either from donor 
or recipient origin depending on the intensity of the conditioning regimen and if the graft was 
not T-cell depleted. Long-term, the immune system is reconstituted by cells of donor origin. 
CD8+ T-cells can regenerate within 2 to 3 months following HSCT as they are able to 
clonally expand but is, early in the process, associated with an impaired functional immunity 
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to specific antigens. CD4+ T-cell reconstitution relies on the thymic production of naïve T-
cells. Therefore, CD4+ T-cells recover later than memory CD8+ T-cells leading to an 
inversion of the CD4/CD8 ratio. Thus, the CD8+ memory T-cells respond faster to previously 
encountered pathogens but present a skewed repertoire and limited response to infection. 
Naïve T-cells of donor origin issued from thymic maturation regenerate later (> 1 year) but 
present a broader repertoire and a better reactivity against infection (Figure 5). Broadening of 
the T-cell repertoire is delayed when the graft is T-cell depleted or issued from a CD34+ 
purification but also when clinical events and parameters such as aGVHD, age and total body 
radiation (especially in the elderly) impair the thymus function 89,90. 
 
Figure 5: T-cell reconstitution (adapted from EBMT handbook) 
Humoral immunity is vital to prevent exogenous infections. Functional humoral immunity, 
such as specific antiviral IgG, persists for several months after HSCT and some preparative 
regimen-resistant recipient plasma cells can persist for years following HSCT 91,92. Early after 
HSCT, B-cells can also come from donor origin and present naïve and memory phenotype 
that have already undergone positive and negative selection in the donor 92. These donor 
origin B-cells contribute to the early antiviral adaptive response and disappear after some 
months mainly if there is no antigen stimulation. B-cell reconstitution after HSCT is slow and 
may take up to 2 years after HSCT. This is particularly true in patients affected by chronic 
GVHD and/or its treatment and is related to the presence of functional helper CD4+ T-cell 
reconstitution since they are necessary for B-cell activation 93. The slow B-cell reconstitution 
can be associated with development of late infections 94. Furthermore, B-cells have been 
associated with cGVHD. Elevated plasma BAFF (B cell-activating factor, a TNF family 
member, role in peripheral B cell selection and survival) levels contribute to B-cell 
overactivation in chronic GVHD patients 95. Note that B-cell reconstitution is faster in 
children. Functional humoral immunity to infections is essential to reduce the risk for late 
complications, therefore, vaccination initiated at 3–24 months is required post-HSCT to reach 
acceptable protective antibody levels 96. 
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1.4.3 CMV Infection/Reactivation post-HSCT 
Despite the changes in patient conditioning (from MAC to RIC) and improved management 
of the immunosuppressive state, infections remains one of the main severe complications 
post-HSCT (Figure 6). 
Phase Pre-engraftment Post-engraftment Late phase 
days post-HSCT +0 to +30 +30 to +100 +100 to >365 
Risk 
Factors 
Neutropenia, Barrier 
breakdown, ↓T-cells, 
↓B-cells, Functional 
asplenia 
↓T-cells, ↓B-cells, 
Functional asplenia, 
Acute GVHD and 
associated treatment 
↓T-cells, ↓B-cells, 
Functional asplenia, 
Chronic GVHD and 
associated treatment 
HSCT complications Rejection Graft Failure Relapse 
Bacteria 
Gram – bacilli  Encapsulated bacteria 
Gram + organisms  
Fungi 
Aspergillus spp 
Candida spp  
 Pneumocutis jiroveci 
Viruses 
HSV 
 CMV 
 VZV 
 EBV / PTLD 
Other viruses: HHV-6, respiratory and enteric 
Figure 6. Chronology of predominant infections post-HSCT (adapted from EBMT handbook, and 
Tomblyn et al. 96 
In general after the first month following HSCT, patients are at risk for CMV. Primary 
infection is defined by the detection of CMV in the blood or plasma of patients with a 
pretransplant negative CMV serology or a seroconversion with the production of specific IgG 
or IgM. The latter is rarely seen early after HSCT. Reactivation of a latent CMV infection is 
defined by the detection of virus, viral antigen, or nucleic acid in patients with a pre-
transplant positive serology. CMV disease is diagnosed when clinical manifestations occur 
and correlate to the presence of CMV in the organs detected by CMV DNA quantitation, viral 
isolation, rapid culture or immunohistochemistry 97: CMV can cause end-organ disease such 
as pneumonia, retinitis, hepatitis, or gastroenteritis. Today, with improved control and 
management of CMV, the incidence of early CMV disease is rather low but the cumulative 
incidence of CMV disease at one year was found up to 10% due to the increased risk of 
developing late CMV disease 98,99. Thus, despite improvement in management strategies, 
CMV remains a leading cause of morbidity and mortality also due to its indirect effects. It 
has, for example, been shown that patients with CMV infections have a higher risk for 
secondary bacterial and fungal infections either due to CMV itself or due to side-effects from 
antiviral therapy 100.  
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CMV infection and disease are directly correlated with the T-cell reconstitution through 
diverse mechanisms such as cytokine production and MHC expression. The main risk factor 
for CMV disease is the serological status of the donor (D) and recipient (R): The D-/R- 
combination has the lowest risk of CMV infection. Primary infection might occur through 
infusion of blood products from a CMV-seropositive donor or through other normal sources 
of CMV such as excretion of CMV in body fluids from children or through sexual 
transmission. Today, the risk for transfusion transmitted infection is very low due to the use 
of “CMV-safe” blood products. CMV-seropositive patients and especially those with a 
CMV-seronegative donor (D-/R+) have the highest risk for CMV disease. Without 
prophylactic treatment approximately 70% of patients would develop a CMV infection 101. 
The D-/R+ combination in unrelated donor HSCT (with myeloablative conditioning only) is 
associated with decreased overall survival as compared to the D+/R+ combination, repeated 
CMV reactivations, and increased risk of CMV disease due to a delayed T-cell 
reconstitution102,103. Other factors for CMV reactivation after HSCT include the conditioning 
regimen (at least within the first year following the procedure), treatments that may affect the 
immune response such as treatment associated to treat GVHD (corticosteroids), and the use 
of unrelated or mismatched donors 104.  
 
1.4.4 Acute and Chronic Graft-versus-Host Disease and CMV 
After HSCT, CMV and GVHD often occur concomitantly. Thus, the correlation between 
acute GVHD with CMV has been studied to characterize the exact relationship between these 
two clinical events 105. An epidemiological study showed a higher risk of CMV reactivation 
and pneumonitis in patients with aGVHD. The increased risk for CMV reactivation may also 
be explained by the immunosuppressive therapy used to treat aGVHD, such as high doses of 
corticosteroids 106-108. An association between CMV infection and chronic GHVD has been 
proposed 109 as CMV reactivations seem to be a risk factor for the development of cGVHD 
possibly associated with the inflammatory environment 110. Antibodies against CD13, a 
marker highly expressed on infected cells and present on all cells that may be infected by 
CMV, were found in patients developing cGVHD suggesting that CMV infection may trigger 
the humoral immune response toward autoantigens 111. Therefore, removal of CD13+ cells 
was suggested to decrease the risk of CMV infection and thereby associated cGVHD 112. 
Also other studies have shown that CMV infection is a risk for more severe cGVHD and 
early intervention based on PCR monitoring was suggested to decrease the risk 113. In contrast 
to cGVHD, the question whether CMV increases the risk for aGVHD remains controversial 
114-116: A bidirectional relationship between CMV infection and aGVHD is feasible due to the 
pro-inflammatory function of the virus and the cross-recognition of the CMV-specific T-cells 
responsible for alloreactivity 117,118  
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1.5 CMV-SPECIFIC T-CELLS IN PATIENTS WITH CANCER 
 
1.5.1 Viral Infection and Cancer 
A correlation between virus and cancer was proposed already the in early 1950s since virus 
can exchange genetic material with the host cell. Main oncoviruses known today in humans 
are papillomavirus (cervix cancer), hepatitis B and C virus (liver cancer) and EBV 
(lymphoma and post-transplant lymphoproliferative disorder). 
Human CMV is not an oncovirus but its association with cancer has been investigated for 
decades as there is evidence of its role in several malignancies. It was described by Geder et 
al. during the 1970s to affect proliferation, survival, angiogenesis, invasiveness and immune 
modulation of tumor cells infected in vitro 119. CMV could then be involved in 
“oncomodulation”, a term and concept suggest by Michaelis et al. to explain the role of CMV 
in human cancer; that is, its ability to catalyze the oncogenic process 120. CMV has been 
found at higher frequency in tumor tissues of several malignancies such as colon cancer, 
prostate cancer, breast cancer or glioma 5-7,121,122. But is CMV a player in the cancer 
pathogenesis or CMV has only an increased tropism for tumor cells? 
 
1.5.2 Molecular Effects of CMV leading to Oncomodulation 
Many CMV immune evasion strategies are common to tumor escape mechanisms and 
oncogenesis: modulation of apoptosis, angiogenesis, cell adhesion and evasion, genomic 
injury and transcription factor activity. Therefore, CMV-infected tumor cells could see their 
oncogenesis proprieties improved. Many CMV proteins are involved in modulation of host 
cell controlled growth. IE1 and IE2 proteins have been described to inhibit the induction of 
apoptosis, which is a common feature of cancer cells 123. CMV protein UL36 and UL37 
promote an anti-apoptotic effect by inhibiting the Fas-mediated apoptosis and Bax/Bak 
activity 120. CMV is also known to downregulate NCAM, a cell adhesion molecule that may 
lead to enhanced tumor cell migration 124. Angiogenesis can be enhanced by CMV IE1 
protein that stimulates the expression of IL-8, a promoter of tumor angiogenesis 125. As 
mentioned earlier, CMV is able to decrease the host cell surface expression of MHC class I 
and II allowing the tumor cell to escape the T-cell immune response (Table 1) 126. Finally, the 
viral protein UL76 has been shown to induce chromosome aberrations contributing 
significantly to genetic instability, which is a major cancer promoter (Figure 7) 127. CMV has 
been detected and involved in various cancers, yet, the clear implication of the virus remains 
unclear. Does it lead to tumor transformation, improve the oncogenesis or only have an 
affinity for tumor cells that rapidly expand? Regardless, the idea to target CMV for cancer 
therapy has come back this last decade with several clinical trials using CMV-directed 
adoptive cell therapy 128.  
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Figure 7 CMV proteome involved in modulation of host cell controlled growth, adapted from Herbein 
G et al. 121 
 
1.5.3 CMV in Cancer: Glioblastoma Multiforme and Pancreatic Cancer 
Glioblastoma multiforme (GBM) are brain tumors usually highly malignant with a low 
median survival about 14,6 months and a two-year survival of 30%. Treatment options are 
few and inadequate: surgery, chemotherapy (temazolomide) and radiotherapy 129. 
CMV infection and its role in GBM pathogenesis have been controversial since the first 
report and many studies have confirmed or refuted it 122,130. The role of CMV in GBM is still 
unclear but few specific oncomodulatory proteins have been described to participate in the 
biology of GBM: angiogenesis (pp71, US28, gB), invasion (US28, gB), stem cell 
maintenance and immortalization (IE1) and immunomodulation (cmvIL-10) 131. Furthermore, 
CMV specific T-cells demonstrated a specific killing of autologous GBM cells suggesting 
that a CMV-directed adoptive cell therapy for patients with glioma may be possible 132. A 
phase II randomized trial using valganciclovir prophylaxis in a small cohort of patients with 
GBM showed a higher median survival of valganciclovir treated patients compared to the 
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untreated group 133,134. A possible effect of the antiviral treatment is that CMV infection 
promotes the dissemination of tumor cells. Chemotherapy fails to induce tumor cell death 
while valganciclovir treatment may suppress CMV proliferation, which restores the 
sensitivity to chemotherapy. There are limitations to this study making interpretation of the 
results difficult. Therefore, additional studies of antiviral strategies and CMV-based 
immunotherapy for glioma are warranted and ongoing, suggesting that immunotherapy 
combined with chemotherapy after surgery may be a safe novel treatment option and may 
offer clinical benefit for patients with recurrent GBM 128. 
Pancreatic adenocarcinoma (PDAC) is the most frequent form of pancreatic cancer and has 
the worst prognosis with a five-year survival of 5%. PDAC is usually diagnosed late and 
presents often a resistance to chemo and radiotherapy with only 10-20% of the patients with a 
resectable cancer 135. No correlation between CMV and PDAC has been directly established.  
 
1.6 MANAGEMENT OF CMV INFECTION 
 
1.6.1 Monitoring 
As described earlier, the risk for CMV infection can be estimated by the serological status of 
the recipient and donor 136.  
CMV monitoring after HSCT can be done by different methods. Cell culture is a traditional 
method to detect CMV but is no longer used due to it being too insensitive and slow. The 
antigenemia assay is a method that can be used to rapidly detect the viral pp65 antigen with 
high sensitivity in the peripheral blood leukocytes 137. Its use has decreased in recent years 
since it is semiquantitative and requires trained staff for interpretation. Quantitative PCR 
assays usually with real-time technology are the most sensitive method for detecting CMV 
DNA in whole blood or plasma and high levels of CMV DNA in blood can be a predictor of 
CMV disease 138. However, especially with CMV gastrointestinal disease, CMV blood viral 
load can be negative 139. Detection of CMV mRNA can also be used for monitoring but this 
method is less frequently used today. Immunochemistry for CMV detection can be performed 
on tissue samples and is useful for diagnosis of invasive CMV disease 140.  
 
1.6.2 Antiviral Drugs 
Anti-viral treatment to prevent and manage CMV infection has been improved over the past 
decades, mainly motivated by the post-HSCT risk for complications. Different management 
strategies can be used: Antiviral prophylaxis given especially during the 3 first months post-
HSCT to prevent CMV replication, preemptive antiviral therapy to prevent the development 
of the disease when CMV reactivation has occurred, and treatment of established CMV 
disease. Different antiviral drugs are directed against different viral enzymes: ganciclovir, 
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valganciclovir, valacyclovir, high dose acyclovir and maribavir are directed against pUL97, a 
protein kinase. Foscarnet and cidofovir directly target pUL54, the viral DNA polymerase. 
Choice of treatment is based on the timing of CMV infection 141 (Table 3). More recently 
letermovir, an agent directed against CMV-terminase complex pUL51 and pUL56, was 
shown to be highly effective as prophylaxis reducing the risk for clinically significant CMV 
infection and also improving survival at 6 months after HSCT 142. 
Table 3. Timing of CMV management and treatment. * Rarely used due to toxicity. ** Limited 
efficacy 
1.6.3 Immunotherapy and Vaccines 
As an alternative to antiviral drugs against CMV infection post-HSCT, adoptive T-cells 
therapy has been evaluated as a possible treatment options the last 25 years. 
Already in the early 90s, adoptive transfer of CMV-specific CD8+ T cell clones proved the 
efficiency of the procedure by reconstituting the CMV-specific protective immunity 143,144. 
This T-cell therapy has also been successful for patients with antiviral drug resistance 145. 
HLA class I multimers and streptamers were used to select CMV-specific CD8+ T-cells 
before expansion and infusion into the patients, showing a reduction of their CMV viral load 
and some patients experienced clearance of CMV infection 146,147. Less than 1 million/kg 
bodyweight of a single infusion of a pp65-specific cell dose was shown to be sufficient to 
clear the infection 148. IFNγ capture T-cell technology, without MHC restriction, has proven 
its efficiency by adoptive transfer of CMV-pp65-specific (CD4+ and CD8+) T-cells in a pre-
emptive therapy setting 149,150. Advances in adoptive T-cell approaches allow new strategies 
for T-cell strategies for therapy. For instance, an Ad5f35pp65 vector was successfully used to 
create T-cells specific for CMV, EBV and several serotypes of adenovirus from a single cell 
culture 151. Adoptive T-cell therapy is not yet able to be used as single therapy and acts most 
efficiently as adjunct treatment in anti-viral treatment but can be used as an alternative when 
primary antiviral therapy treatment fails 152. 
Viral replication 
 
                       Diagnosis of                       CMV infection 
                       Viral 
                    Disease 
Timing of 
management 
Prophylaxis 
(all patients) 
Pre-emptive therapy 
(some patients) 
Treatment of established 
disease 
(few patients) 
Ganciclovir Yes* Yes Yes 
Acyclovir  Yes** No No 
Valacyclovir Yes** No No 
Valganciclovir Yes* Yes Yes 
Foscarnet No Yes Yes 
Cidofovir No Yes Yes 
Maribavir No Yes Yes 
Letermovir Yes No No 
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Currently, no CMV vaccine has been licensed, although some vaccines are in late-phase 
clinical trials and its development is a high priority of the National Vaccine Program Office. 
A list of the CMV vaccines currently or recently in clinical trials has been published in 2016. 
This listed 26 trials in phases I and II using different vaccine technologies: DNA, vectored, 
attenuated, recombinant and peptides vaccines targeting mainly pp65, gB and IE1 antigens 
153,154. 
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2 AIMS OF THE THESIS 
 
The general aim of the thesis was to characterize and better understand the evolution of the 
immune response that targets one of the most common human viruses: CMV. For it, the 
investigation was done in different clinical settings: patients post-HSCT and patients with 
brain cancer. 
We aimed, in Paper I and II, to gain insight into the CMV-specific immune response and the 
relationship between GVHD and CMV. 
In Paper III, we aimed to define the function of IL-7 and soluble IL-7R in patients post-
HSCT that are at risk of CMV reactivation and GVHD. 
In Paper IV, we aimed to gain insight into the complex relationship between the CMV 
immune response and patients with cancer to identify the CMV specific immune response as 
a potential biomarker of immune fitness. 
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3 MATERIALS AND METHODS 
 
3.1 ETHICAL IMPLICATIONS AND CLINICAL INFORMATION 
For this thesis, all research was performed on healthy individuals’ and patients’ blood or 
peripheral blood mononuclear cells (PBMC). For each single study, the work was approved 
by the Regional Ethical Review Board in Stockholm (diary number: 2010/760-31/1 for 
Paper I, II and III, diary numbers 2013/576-31 and 2013/977-31 for Paper IV and 
2009/1183-3 for the healthy individuals). All patients agreed to donate blood samples for 
research purposes and informed consent was obtained from them or from their parents or 
legal guardians in the case of children. Each patient was attributed an individual code to allow 
pseudonymization of data. Patients clinical information was collected by the staff from the 
clinical wards. For Paper I (N=277), II (N=23) and III (N=61), when possible, heparinized 
blood was taken before HSCT (time point 0) and at month 1, 2, 3, 6, 12 and 24 after HSCT. 
For Paper II, patients were selected based on HLA-A*02:01 positive and no ATG treatment. 
For Paper IV (N=374), blood was collected from patients with brain (n = 314) or pancreatic 
cancer (n = 60) on the day of surgery before anesthesia of the patient. Patients with brain 
tumor received corticosteroids at time of diagnosis. Samples from sex- and age-matched 
healthy individuals were used as controls for Paper III (n=26) and IV (n=244). All samples 
were processed in the laboratory within 24h.  
 
3.2 WHOLE BLOOD ASSAY AND ELISA 
Whole blood assay (WBA) used for Paper I and IV provides, in contrast to PBMC culture, a 
physiological environment closer to in vivo allowing the study of the immune response to 
specific antigen stimulation. Blood of the individual was first diluted with RPMI medium. 
Diluted blood was then added in duplicates to a pre-coated plate with CMV-pp65 and EBNA-
1 proteins and incubated for a week. Phytohemagglutinin protein (PHA) and antigen-free 
medium were used as positive and negative controls. After the incubation period, 
supernatants of the cell culture were harvested. Note that for Paper IV only, the blood was 
conditioned with IL-2, IL-15 and IL-21 cytokines to gauge the ability of the immune cells of 
patients with cancer to respond to cytokine stimulation.  
Enzyme-linked immunosorbent assays (ELISA) were used to quantify the antigen-specific 
IFNγ production following WBA (Paper I and IV), plasma level of soluble IL-7R (sIL-7R, 
Paper III), and level of antigen-specific plasma IgG (Paper IV). The exact cytokine and 
antibody concentration was evaluated by measuring the optical density correlated with a 
standard curve of known concentration. 
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3.3 CMV-REACTIVE TETRAMER AND FLOW CYTOMETRY 
Flow cytometry was performed for Paper II and III. Tetramers provide the quantification, 
visualization and sorting of antigen-specific (mostly CD8+) T-cells without any in vitro 
manipulation. The three different anti-CMV pp65 HLA-A2*01:02NLVPMVATV tetramers were 
constructed in-house by Dr. Axelsson-Robertson. The mutations a245v and q226a were 
introduced into the sequence of the heavy chain. Mutant a245v, which due to the amino acid 
(aa) substitution from alanine to valine at position 245, reduces the MHC class I-CD8 co-
receptor interaction. Mutant q226a totally abrogates the interaction between MHC class I and 
the CD8 co-receptor due to the aa substitution from glutamine to alanine at position 226 
(figure 8). A tetramer was created from monomeric MHC class I-peptide complexes and 
labeled with the appropriate fluorochrome. 
 
Figure 8. MHC class I molecule with the position a245 marked in green and the position q226 
marked in red (from Dr. Axelsson-Robertson).  
For study II and III, up to 12 different markers were used for a single panel (table 4, a non-
exhaustive list of markers of interest used during this thesis). T-cell populations from patients 
who underwent HSCT were analyzed for IL-7R frequency, memory phenotype, 
exhaustion/activation and TCR affinity to CMV peptide antigen. 
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Marker clone Characteristic 
CD3 UCHT1 identification of T-cell 
CD4 RPA T4 identification of helper T-cell, binds class II MHC 
CD8a SK1 identification of cytotoxic T-cell, binds class I MHC 
CCR7 G043H7 T-cell memory marker, homing marker to secondary lymphoid organs 
CD45RA HI100 T-cell memory marker  
CD279 (PD-1) EH12-2H7 activation/exhaustion marker 
CD127 (IL-7R) R34.34 IL-7 receptor 
CMV wt tet  identification of all CMV-CTL 
CMV a245v tet  identification of CMV-CTL with medium affinity TCR 
CMV q226a tet  identification of CMV-CTL with high affinity TCR 
Table 4: List of the markers analyzed by flow cytometry.  
 
3.4 STATISTICS 
For this thesis, most of the statistical analyses performed were univariate test. Differences 
within each group for comparison between time points post-HSCT were analyzed using 
Wilcoxon matched-pairs signed rank test. Differences between groups of unpaired samples 
were analyzed using Mann-Whitney U-test or Kruskal–Wallis test followed by Dunn’s post-
test. Differences between two groups over time post-HSCT were analyzed by two-way 
ANOVA followed by the Tukey’s test for multiple comparisons to detect differences at 
specific time points. Linear regression was assed to determine the correlation. Survival was 
evaluated by the Kaplan-Meier survival analysis, log-rank test and cox univariate regression 
analysis. 
Multivariate analysis was performed using Cox multivariate regression model (stepwise 
selection) for Paper I and multiple regression to analyze the clinical factors affecting the 
levels of sIL-7R at different time points in Paper III.  
Statistical analysis was performed using GraphPad Prism software, R and Statistical software 
program (version 10). 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
CMV and EBV immune response characterized by specific IFN-gamma production 
post-HSCT correlates with grades of GVHD and CMV reactivation. 
Despite improvement in CMV management post-HSCT, CMV infection and reactivation 
remain major complications in the early months following the procedure. In this study, the 
aim was to analyze the CMV-specific immune response characterized by the IFNγ towards 
CMV-pp65 antigen and its clinical association with complications such as GVHD and CMV 
reactivation. Fresh blood from a large cohort of 277 patients (1244 samples with a median of 
5 samples per patient) followed for 2 years was tested for CMV-pp65 stimulated specific 
IFNγ production. 
Hundred twenty-eight of 277 (46.2%) patients with a pre-transplant positive CMV serology 
were treated at least once for CMV reactivation at a median time of 33 days post-HSCT. The 
median time to aGVHD development was 27 days and 43.7% of the patients presented 
symptoms of grade II-IV aGVHD. We observed a significant recovery of the anti-CMV 
immune response characterized by the specific IFNγ production at the first month post-
HSCT. Normalization of the IFNγ production between patients and time points was 
established by evaluating the relative anti-CMV IFNγ response in relation to the response 
magnitude induced by the basal IFNγ response for each individual sample. Similarly, the 
relative CMV-specific IFNγ response presented as well the month 1 post-HSCT of interest 
with a significant higher relative IFNγ production the first month post-HSCT (p<0.001). 
Normalization of the IFNγ production may allow to evaluate the T-cells’ ability to respond to 
a given antigen stimulation regardless the differences in cell number between patients and 
samples. Looking closer at the parameters that may affect the CMV-specific IFNγ response, 
we observed that patients with a positive CMV serology and those treated with ATG showed 
a higher IFNγ production especially at month 6 and 12 post-HSCT (p<0.001) compared to the 
CMVneg patients that did not receive ATG. ATG treatment is used mainly in patients 
transplanted with unrelated donors but, as observed in our study, may create disturbances in 
the immune reconstitution 155.  
Acute GVHD and the immunosuppressive treatment given for GVHD are known to increase 
the risk of CMV reactivation 106,141 while patients with CMV reactivation might have a higher 
risk of developing aGVHD 115. Yet, the role of a CMV-specific immune response in GVHD 
development still requires understanding. We observed that the CMV-specific IFNγ 
production gradually decreased with increasing severity of the aGVHD (p<0.001) (Figure 
9A-B). Since similar observations were made in response to EBV antigen and the positive 
PHA control, we assumed that the correlation was due to the prophylactic or therapeutic 
immunosuppressive treatment. Furthermore, patients who were unable to respond to antigen 
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stimulation (CMV and positive controls) showed a decreased survival. Akin to our previous 
observation, we assumed that this correlation revealed the impact of different grades of 
aGVHD on survival as the patients with the most severe grade of aGVHD (III-IV) presented 
survival rate much worse than any other grade of aGVHD (0-II). 
Furthermore, CMV reactivation also appeared to stimulate the CMV-specific IFNγ 
production. Patients with CMV reactivation had greater CMV-specific IFNγ production 
regardless of aGVHD grade (p<0.011) as IFNγ response is one of the major arms of the 
immune defense toward CMV (Figure 9C) 156. 
 
Figure 9. Impact of aGVHD and CMV reactivation in the CMV-specific IFNγ response in patients 
pre- and post-HSCT. A. Patients were grouped by aGVHD grades: 0-I and II-IV. B. CMV-pp65 
specific IFNγ production at month 3 post-HSCT per aGVHD grades. C. Patients were separated into 4 
groups by the CMV infection status and aGVHD grades. 
Although we observed that the CMV-specific IFNγ response was greatly affected by many 
clinical parameters, this did not seem to be important for the patients’ survival post-HSCT as 
the strongest clinical parameters in our cohort were aGVHD (p<0.001) or the use of donor 
lymphocyte infusion (DLI, p<0.026) that is given in relapse patients 157. Mild grade of 
chronic GVHD had a beneficial effect on patients’ survival, which could be explained by its 
protective effect on relapse 158. Unexpectedly, female patients had a decreased survival post-
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HSCT (p=0.01) (Table 5). This observation goes against previous data showing that male 
patients receiving a graft from a female presented a higher risk of both aGVHD and non-
relapse mortality 159. 
 beta HR (95% CI for HR) p.value 
Gender -0.63 0.53 (0.35-0.81) 0.003 
DLI 0.58 1.8 (1.07-3) 0.026 
aGVHD grade II 0.4 1.49 (0.92-2.4) 0.11 
aGVHD grade III-IV 1.79 5.96 (3.2-11.12) <0.001 
cGVHD grade I -1.13 0.32 (0.18-0.56) <0.001 
cGVHD grade II -0.9 0.41 (0.16-1.03) 0.06 
cGVHD grade III -1.41 0.24 (0.07-0.83) 0.02 
Table 5: Cox regression, multivariate analysis of the identified variables from the univariate analysis 
by stepwise selection. 
This paper presents the anti-CMV immune response post-HSCT as characterized by the 
specific IFNγ production in association with crucial clinical parameters. In general, the anti-
CMV response was similar to the response specific to EBV and the positive control which 
more reflects the general immune fitness of the different patients post-HSCT than an 
“antigen-specific” response. Further investigation is needed to better characterize what 
belongs to the general immune fitness and what belongs to the specific antigen response in 
this immunosuppressive clinical setting. The timing of intervention and clinical events also 
needs to be investigated to better understand the relationship and network between clinical 
parameters and the viral-specific immune response. 
 
4.2 PAPER II 
CMV-specific CD8+ T-cells with different TCR affinities segregate T-cell phenotypes 
and correlate with chronic GVHD in patients post-HSCT 
Adoptive T-cell therapy (ACT) for CMV infection/reactivation has become a potential 
alternative to standard antiviral treatment to overcome the immunodeficient state of patients 
post-HSCT. Optimizing T-cell products for ACT might be achieved by a better 
characterization of the mechanism and biology providing an effective and long-lasting 
immune protection against transformed cells and pathogens like CMV. There is still room to 
improve the ACT, therefore, the aim of this second study was to characterize the CMV-CTL 
with TCRs of different affinities using three MHC class I-CMVNLVPMVATV peptide tetramers 
and to further correlate those different populations with clinical parameters such as CMV 
reactivation and GVHD. 
The q226a mutant HLA-A2 tetramers ,which totally abrogates the interaction between MHC 
class I and the CD8 co-receptor, was functionally validated as we did not observe any 
inhibition of IFNγ production upon CMV-peptide stimulation while using CD8 blocking 
antibody. The wt tetramer binds to all CMV-CTL regardless of their TCR affinity, mutant 
a245v tetramer binds to CMV-CTL with medium and high-affinity TCR, and the mutant 
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q226a tetramer binds only to CMV-CTL with high-affinity TCR. Reconstitution of the CMV-
CTL was then investigated in 23 patients during a 12 months period post-HSCT using the 
three different tetramers. CMV-CTL with high affinity TCR were found at higher frequencies 
over time post-HSCT (p=0.007) while CMV-CTL with medium-affinity TCR were present at 
a lower proportion as compared to CMV-CTL populations with low- and high-affinity TCRs 
(p<0.004) (Figure 10). 
 
Figure 10. HLA-A2 CMV tetramer-reactive CD8+ T-cells and CMV-specific T-cells post-HSCT. A. 
Differences between the CMV-CTL subpopulations frequency in CD8+ T-cells. B. Proportion 
analysis of the different subpopulations (low, medium, high-affinity) in the total of CMV-CTL. 
Next, we observed that CMV-CTL with high affinity TCR were mostly effector memory T-
cells (CD45RA− CCR7−) as compared to CMV-CTL with low- and high-affinity TCRs 
which were mostly terminally differentiated (CD45RA+ CCR7−) phenotype. High-affinity T-
cell clones were previously described to exhibit different memory phenotypes 160. 
Furthermore, high-affinity T-cells enrich the memory pool during secondary response 
suggesting a long-lasting immune protection 161,162. 
We observed a higher PD-1 expression among CMV-CTL with high-affinity TCR compared 
to the medium-affinity CMV-CTL (p=0.013). The proportion of high-affinity CMV-CTL in 
the CD8+PD1+ was higher than the low-affinity CMV-CTL at the first month post-HSCT 
(p=0.012). Within the CD8+PD-1+ T-cell population, high-affinity CMV-CTL were found at 
higher proportion compared to low-affinity CMV-CTL (p=0.012) at month 1 post-HSCT. 
Furthermore, high-affinity CMV-CTL were found at higher frequency, mostly early post-
HSCT in the CD8+PD-1+ T-cell population compared to the total CD8+ T-cell population 
(p<0.001) (Figure 11). Expression of PD-1 can be a marker of cell exhaustion or T-cell 
dysfunction but also of antigen-experienced T-cells 163: CMV-CTL expressing PD-1 were 
described to conserve their ability of produce cytokines without cytotoxic or proliferative 
function 164. 
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Figure 11. PD-1 expression of CMV-CTL with different TCR affinities over time post-HSCT. A. 
Proportion of the high/medium/low-affinity CMV-CTL in the CD8+ PD-1+ T-cell population. B. 
Comparison of the high-affinity CMV-CTL frequency between the total CD8+ T-cell population and 
the CD8+ PD-1+ T-cell population. C. Pie charts with the proportion of high/medium/low-affinity 
CMV-CTL the total CD8+ T-cell population and the CD8+ PD-1+ T-cell population at month 1 and 2 
post-HSCT. 
While analyzing the clinical factors that may affect the CMV-CTL, patients diagnosed for 
CMV reactivation (11/23) were found to have a non-significant (p=0.067) higher frequency 
of CMV-CTL compared to those who did not present CMV reactivation. No correlation 
between CMV reactivation and the different CMV-CTL affinities was found. We highlighted 
that patients with chronic GVHD showed a higher proportion of high-affinity CMV-CTL 
(p<0.001) compared to patients who did not show symptoms of cGVHD. Reversely, patients 
with cGVHD shower a lower proportion of low-affinity CMV-CTL (p<0.001) compared to 
those without cGVHD (Figure 12). Earlier studies have already suggested that T-cell 
populations with high affinity TCRs were the most susceptible to be cross-reactive 165,166.  
This second manuscript presents the reconstitution of CMV-CTL with different TCR 
affinities in patients post-HSCT. CMV-CTL population with high-affinity TCR was at high 
proportion in the CD8+ PD-1+ population suggesting antigen-experienced T-cells. They had 
an effector memory phenotype while CMV-CTL with medium- and low- affinity TCR had a 
terminally differentiated memory phenotype. The correlation between cGVHD and high 
proportion of CMV-CTL with high-affinity TCR needs further investigation. Indeed, 
selection of cytotoxic T-cell population with high affinity TCR was suggested in the past to 
 34 
be beneficial for ACT 167 but also associated with increased risk of alloreactivity like the 
present study suggests. 
 
Figure 12. CMV-CTL frequency, low and high-affinity proportion correlated with cGVHD. Green 
circle: No cGVHD; orange square: cGVHD (I-III). 
 
4.3 PAPER III 
Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease 
(GVHD) in children and adults. 
IL-7 is an essential cytokine which, via the IL-7R, induces T-cell homeostatic proliferation 
and survival. IL-7 is necessary for maintenance and expansion of immune responses against 
infection or reactivation post-HSCT. Reversely, increased IL-7 levels are associated with 
autoimmune immune responses and an increased risk of GVHD 168. Soluble IL-7R is also 
associated with development of autoimmune responses when present at increased levels 169 
but is also described to bind free IL-7 and consequently inhibit the IL-7/IL-7R signaling 
pathway. Therefore, we hypothesized that altered levels of sIL7R may be involved in GVHD 
and immune response towards viral reactivation post-HSCT. 
Twenty-nine children and 32 adults were studied post-HSCT to determine the levels of IL-7 
and soluble IL-7R in association with clinical events. At a membrane-bound level, CD4+ and 
CD8+ T-cells from children presented a higher expression of IL-7R over time post-HSCT 
compared to the adult cohort (p<0.05). No differences were found in the sIL-7R level 
between adults and children but both groups had an increased level of sIL-7R over time post-
HSCT. 
Correlation with clinical events showed that, in adults, a decreased level of plasma sIL-7R in 
patients was associated with any grade of acute GVHD (p<0.05) and CMV 
reactivation/infection (month 2 post-HSCT). Acute GVHD and associated 
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immunosuppressive treatment may be responsible for the delay in immune recovery and, 
consequently, is associated with the increased risk of CMV reactivation 115,141,155. By 
multivariate analysis, ATG treatment was associated with lower sIL-7R levels in plasma 
(p=0.06) which is in line with our previous observation on GVHD and associated treatment 
(Table 6). Donor type was also an important factor associated with sIL-7R levels as those 
who received a graft from siblings had higher sIL-7R levels between two and six months 
post-HSCT (p<0.05) compared to patients receiving unrelated donor grafts. Stem cells from 
siblings may induce a better immune reconstitution than those from unrelated donors which 
could be represented by the higher level of sIL-7R level observed in our study 170. This might 
also be due to the common practice to use ATG when transplants are performed from 
unrelated donors.  
Factor HR 95% CI p-value 
1 month after HSCT 
Sibling donor 1.23 0.95–1.61 0.13 
aGVHD 0.76 0.58–0.99 < 0.05 
2 months after HSCT 
Sibling donor 1.31 1.01–1.70 < 0.05 
CMV infection 0.83 0.64–1.08 0.17 
aGVHD 0.70 0.55–0.90 < 0.01 
3 months after HSCT 
Sibling donor 2.23 1.34–3.71 0.004 
aGVHD 0.91 0.70–1.20 0.50 
ATG 1.66 0.99–2.78 0.06 
6 months after HSCT 
Sibling donor 1.86 1.21–2.86 < 0.01 
aGVHD 0.77 0.58–1.04 0.09 
ATG 1.30 0.83–2.04 0.26 
12 months after HSCT 
Sibling donor 1.30 0.97–1.74 0.09 
HLA-Mismatch 2.12 1.59–2.82 < 0.001 
Table 6. Multivariate analysis of factors affecting sIL-7R levels over time post-HSCT.  
This third study suggests an association of low level of plasma sIL-7R with acute GVHD. 
Soluble IL-7R could have a neutralizing role of free IL-7. We hypothesize that IL-7/sIL-7R 
complex is a “double-edged” sword as free IL-7 induces immune reconstitution and 
consequently promote the immune response towards infection such as CMV while increasing 
the risk of GVHD post-HSCT. In this setting, sIL-7R could play a role of “buffer” until 
release to ensure T-cell survival and proliferation. 
 
4.4 PAPER IV 
Epstein-Barr virus- and Cytomegalovirus-specific immune response in patients with 
brain cancer. 
Antiviral immunity to common pathogens such as CMV and EBV, with prevalence above 
80% in adults, is an integral and dominant component of immune competence in humans. 
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Patients with malignant glioma (GBM) and pancreatic cancer present the poorest prognosis 
and impairment of cellular immune responses may predict disease progression and 
consequently patient’ survival. The last study presents the CMV-specific immune response in 
a different clinical setting: chemotherapy-naïve patients with advanced cancer. The aim was 
to investigate if CMV/EBV-directed immune reactivity characterized by the antigen-specific 
IFNγ production could be used as a clinically relevant biomarker of immune 
competence/exhaustion in patients with brain tumor (GBM and pancreatic cancer). 
First, CMV-pp65-specific plasma IgG level were lower in patients with GBM compared to 
age- and sex-matched healthy individuals and those with pancreatic cancer (p<0.05 and 
p<0.001, respectively). Furthermore, among seropositive patients only, those with lower IgG 
titers (< median) at time of surgery displayed a decreased overall survival compared to those 
with higher titers of antibody (p=0.017) (Figure 13). An earlier study by Amirian et al. 
showed that patients with the lowest level of anti-CMV IgG exhibited the highest risk for 
glioma but no association with survival was made 171.  
 
Figure 13. A. IgG recognition of CMV-pp65 in plasma of healthy donors (HD) and patients with 
brain tumor or pancreatic cancer. B. Survival of the patients with GBM based on the CMV-specific 
IgG levels. Top panel: all GBM patients. Bottom panel: GBM patients with detectable anti-CMV IgG. 
GBM glioblastoma multiforme, A astrocytoma, OA/OD oligoastrocytoma/oligodendroglioma, M 
metastatic disease, Panc Cancer pancreatic cancer 
Secondly, the CMV-pp65 cellular immune response also appeared to be low in patients with 
GBM compared to healthy individuals and patients with pancreatic cancer. A similar 
observation was made toward the EBNA-1 and the positive control (PHA) cellular immune 
response suggesting that patients with glioma display a dysfunctional immunological control 
of latent infection. This dysfunction may be representative of the general immune impairment 
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due to the corticosteroids used to treat the brain inflammation in those patients but also from 
immunosuppressive agents secreted by the tumor itself 172,173.  
 
Figure 14. Absolute values and difference between unconditioned and IL-2/IL-15/IL-21 cytokine 
conditioning (ΔIFNγ production) of the CMV-pp65-specific IFNγ production for each group 
Next, we observed that the responsiveness to cytokine conditioning characterized by the 
antigen-specific IFNγ production differences varied between patients groups, but also 
antigens themselves, suggesting different degrees of sensitivity to cytokine due to immune 
impairment that differs between cancer types. Yet, cytokine conditioning was able to improve 
the antigen-specific IFNγ response regardless of existing immunosuppression in patients with 
GBM (increased IFNγ production median above 200 pg/ml) (Figure 14). Interestingly, 
exclusively under cytokine conditioning, among the responding patients with GBM, those 
exhibiting a higher EBV-specific IFNγ production (> median) showed an increased overall 
survival compared to those with weak EBV-specific cellular immune IFNγ production (753 
vs 370 days, p < 0.001). T-cell response to cytokine stimulation may differ due to the degree 
of exhaustion observed in patients with brain cancer 172. 
In this report, the cellular immune response to viral antigens was different between groups of 
patients and did not seem to impact directly patients’ survival. Altogether, this leads us to 
conclude that those observations reflected the general and complex immunological condition 
of patients with cancer in their ability to respond to common pathogens and to cytokine 
stimulation. 
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5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
It feels like this thesis is only a drop in the ocean of questions around the CMV specific 
immune response and its broad implications. And we come out from this with even more 
questions. Yet, our contribution brings some new information to our understanding of the 
CMV immune response in patients post-HSCT and with solid tumors. In this thesis, we 
looked at the relationship of CMV and the CMV specific T-cell response: the virus is 
triggering the immune system, shaping the phenotype, memory T-cells and frequency that 
may participate to clinical events while the general immune response together with CMV-
specific one is crucial for the control of the virus reactivation:  
In our studies post-HSCT, we observed that patients with an inexistent IFNγ production 
toward mitogen stimulation had a lower overall survival post-HSCT presumably due to 
deficient T-cell reconstitution. Deficient IFNγ production may be a marker for factors 
negatively affecting patient survival, mainly T-cell reconstitution, in patients post-HSCT 174. 
The IFNγ have been earlier described to have a positive effect for CMV reactivation control: 
IFNγ is responsible for recruitment and activation of macrophages, T-cells, and NK cells 175. 
It triggers the T-cell differentiation toward an antiviral effector function and increase the 
MHC expression and antigen presentation. Low level of CMV-specific IFNγ was correlated 
with high-level viremia and CMV disease post-HSCT using QuantiFERON-CMV-assay 
176,177 and by intracellular staining: Patients with T-cells and more especially the CD4+ T-cell 
subset and that do not produce IFNγ upon CMV stimulation were showing a lower peak of 
CMV than patients who did not produced the cytokine. Furthermore, in a study by Avetisyan 
et al, no patient, who developed CMV disease, did have a detectable IFNγ production 178 To 
identify patients at risk for CMV disease, Özdemir et al reported that TNFα was a potential 
biomarker: While increased plasma level of TNFα during the first week post-HSCT may 
predict the development of CMV reactivation 179, inability of the CMV specific-CD8+ T-cells 
to produce TNFα upon CMV stimulation was associated with the reactivation of the virus 180. 
In our study, however, low levels of IFNγ production were not correlated with CMV 
reactivation or disease, and did even show an opposite trend in after month 6 post-HSCT 
where the patients with CMV reactivation had a higher CMV-specific IFNγ production. This 
observation may be due that most CMV reactivations occur before the 6 month time point 
and patients controlling CMV develop IFNγ responses. However, mitogen-specific IFNγ 
production was found at higher level in patients that did not develop CMV reaction and 
aGVHD which reflects the general T-cell function of those patients from month 2 to 6 post-
HSCT. 
Functional IFNγ producing CMV-CTL can provide protection against CMV reactivation and 
are essential to prevent multiple reactivation of the virus post-HSCT as Moins-Teisserenc et 
al. demonstrated 10 years ago 181,182. Multiple reactivations are the hallmark of patients 
unable to control CMV and are also associated with antiviral resistance, development of 
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CMV disease, and increased not-relapse mortality 103. Furthermore, patients, who 
experienced an early CMV antigenemia, presented a higher frequency of CMV-CTL as 
compared to those who did not 180. Lack of IFNγ producing CD8+ and CD4+ CMV specific 
T-cells were also associated with a risk of developing active CMV infection 183. Only a trend 
in this direction was observed in our second study but due to the small number of patients, we 
could not look at the timing of reactivation (early versus late). Due to the phenotype of the 
CMV-specific CD8+ T-cells with high-affinity TCR and the correlation with clinical events, 
we speculated that those cells may be more suitable for anti-CMV protection but also 
associated with alloreactivity (GVHD). Söderberg et al showed that patients with CMV 
disease later developed extensive cGVHD with the association of CD13 (marker of myeloid 
cells)-specific antibodies production towards affected organs110. We could speculate the 
involvement of the CD4+ T-cells, knowing their crucial involvement on the enhancement of 
antibody-mediated immunity, in the humoral immune response activation against the CD13 
autoantigen 184. Furthermore, early intervention against CMV infection based on PCR 
reduced the risk of extensive cGVHD 113. Together, these information show that a possible 
correlation between immune response against CMV and cGVHD. T-cells with high-affinity 
TCR for peptide-MHC (pMHC) may have enhanced function as compared to low-affinity 
that require a higher level of pMHC and more co-receptor stabilization and stimulation for T-
cell activation 185,186. The severe down-side of those T-cells with high-affinity is the risk of 
TCR cross-reactivity to self-antigen as it happened in a clinical trial on patients with 
myeloma and melanoma using engineered T-cells expressing an affinity-enhanced TCR 187. 
Along with this cross-reactivity risk of the T-cells with high-affinity TCR, in the context of 
HSCT, a recent study reported homology peptide sequences presented to TCR between CMV 
and human origin. The authors suggested that, given the distribution of those targeted 
peptides (skin, gastrointestinal tract) and the correlation with the patients symptoms of 
GVHD, an involvement of a cross-reactivity may contribute to the initiation of GVHD in 
some patients 118. It should be noted, however, that adoptive transfer of CMV-specific T-cells 
using clones or lines (therefore possibly with higher TCR affinity) has been clinically applied 
over the last decades without showing any increased risk of cGVHD 143,144,188. 
Patients at high risk for CMV reactivation (i.e those with aGVHD and treated with 
corticosteroids) were described to present an impaired function of the CMV-CTL while the 
number of these cells was not different to those who were not a risk of reactivation 180. In our 
study, no difference in the frequency of CMV-CTL regardless of the incidence of aGVHD 
was observed. We found instead a correlation between a higher frequency of CMV-CTL and 
development of cGVHD but no time-dependent analysis was performed. Reversely, the 
number of CMV-specific IFNγ produced was correlated with the severity of GVHD as 
steroid treatment commonly is associated with  delayed T-cell reconstitution and can also 
affect the function of the CMV-specific T-cells 180,189. While the development of aGVHD was 
not associated with the PHA specific IFNγ production at month 3 post-HSCT, Yong MK et 
al. showed a strong association of the amount of PHA specific IFNγ production with the 
aGVHD severity and within patients with aGVHD; those with a low production had a 
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reduced overall survival at 12 months post-HSCT and it was predictive for increased non-
relapse mortality 174.  
The T-cell reconstitution is as well correlated with plasma level of IL-7 by expanding mature 
T-cells and enhancing production of naive T-cells but this cytokine was also involved in 
driving and worsening GVHD 168,190,191 thus IL-7/sIL-7R complex is involved in the delicate 
balance post-HSCT. sIL-7R is generated by polymorphism in the IL-7R gene (rs6897932, 
amino-acid substitution in exon 6) leading to increased splicing in the transmembrane domain 
of exon. IL-7 contributes to the immune response towards infection but the single nucleotide 
polymorphisms (SNP) of IL-7R responsible for the soluble form have been correlated with an 
increased risk of autoimmune disease 169 and alloreactivity manifested by GVHD 192. Soluble 
IL-7R role on IL-7 is poorly understood and two models are discussed: 1) plasma sIL-7R 
limits the availability of IL-7 for T cells or 2) potentiates the bioactivity of IL-7 by protecting 
IL-7 with a short term inhibitory function for a later availability of IL-7 193,194. In the third 
study, we observed a lower level of sIL7-R in patients with aGVHD and with CMV 
reactivation but CMV reactivation was not significant in the multivariate analysis the low 
level of sIL-7R suggesting GVHD as a more important driving force on the level of sIL7-R. 
Recent studies from Kielsen K et al. suggested a similar finding with a low level of sIL-7R 
and high ration IL-7/sIL-7R may be predictive for the risk of GVHD and CMV reactivation 
on larger cohorts of patients 195,196. They further showed that the specific donor rs6897932 TT 
genotype of SNP in the exons of the IL-7Rα was associated with those increased risk as 
compared to rs6897932 CC and rs6897932 CT. This specific genotype of the donor were 
found to also be associated with an increased risk of disease relapse compared to CC and CT 
donors 192. 
In our study in patient with solid tumors, we reported that the patients with GBM had 
generally a lower IFNγ production against viral and mitogen antigens and were less 
responsive to cytokine stimulation as compared to other types of brain tumors and pancreatic 
cancer. The IFNγ production to specific antigens was used as biomarker for immune fitness 
since impaired IFNγ production is also a characteristic of advanced immune exhaustion that 
follows the loss of IL-2 production and later on of TNFα production. Immune exhaustion can 
be the result from repeated antigen exposure such as chronic viral infection or cancer 197,198. 
The sensitivity to cytokine stimulation may be due to the immune dysfunction such as an 
impaired expression of the cell surface cytokine receptor of the patients with cancer 172. The 
CMV serostatus of the patients was reported by Baumgarten, P. et al. to not be associated 
with overall survival 199 and we confirmed this observation in our study as within the group 
of patients with detectable anti-CMV IgG only, GBM patients with a low humoral anti-CMV 
IgG response presented a decreased median survival as compared to those with anti-CMV 
IgG higher above the median as observed in previous study 171. No such was observed 
regarding the cellular immune response toward CMV antigen unlike the one towards EBNA-
1 and PHA. Like in study I, the IFNγ production against CMV-pp65 did not seem to be a 
factor or a biomarker for the survival of patients with GBM. Under cytokine conditioning 
only, the EBNA-1- and PHA-specific IFNγ production were associated with the patients’ 
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survival. As mentioned for study I, impaired IFNγ production may be a marker for factors 
negatively affecting survival in patients with cancer and response to PHA was earlier 
described as a candidate for biomarker of immune exhaustion in patients with brain tumors 
172,200,201. Furthermore, a recent study by Mohme M et al. presented reduced production of IL-
2 and IFNγ upon PHA stimulation of the peripheral blood lymphocytes indicating a 
dysfunctional response of the peripheral immune cells as signs of immune exhaustion 202. 
Therefore, despite the recent interest of EBV in GBM pathogenesis 203, in the present study, 
the association between its specific IFNγ production and overall survival may be the 
consequence of the general immune fitness of the patients as the relative IFNγ production 
analysis lets suggest. It should be noted that we analyzed the patients only at the time of 
diagnosis and we have not followed the patients with repeated analysis to see what was the 
influence of therapy against GBM. Therefore, the antigen-specific IFNγ production may be 
affected by other clinical parameters that govern patient survival such as use of other 
chemotherapy or radiotherapy, Karnofsky performance status, complete vs incomplete tumor 
excision and the use of steroids but this association was not studied in the present manuscript 
204,205. 
 
CMV is a known pathogen for almost 80 years and its specific immune response has been 
extensively studied since the discovery of the severe symptoms generated by CMV 
reactivation and disease in individuals with immature or immunocompromised immune 
system. Yet, even after all those years, we do not have a total understanding of the CMV-
specific immune response and all its clinical implications. In the most recent decades, we saw 
that the CMV-immune response was not only involved in the protective effect of viral 
reactivation but also in various inflammatory disorders and in cancer with the 
oncomodulation properties. Furthermore, CMV has been shown to shape the general immune 
system and enlist a non-negligible fraction of the memory T-cell population that becomes 
even more prominent in the elderly (memory T-cell inflation) which could enhance the 
immunosenescence. 
It is amazing to see how, such a common “inoffensive” virus, could be involved in so much 
clinical pathology. From being a pathogen to a direct player in the shape of the general 
immune system, there is still so much to learn from the immune response to CMV that may 
extend our knowledge of the immune system to a larger extend. 
Much more can be done following those four studies. First, this thesis obviously lack of 
functional immunology techniques that would help to better understand and characterize the 
complex network between the CMV-specific immune response and the observed clinical 
association. More specifically: 
It is necessary to analyze the function of the different subset of CMV-CTL observed 
in paper II. What are their distinct cytotoxic activities? How do they proliferate? What are 
they producing? We observed differences in the expression of PD-1 between them; thus, it 
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could be interesting to look at the other marker of exhaustion and stimulation (TIM-3, CTLA-
4, LAG-3 etc.) and analyze the impact of corresponding checkpoint inhibitor such as PD-1 
blocking antibody on the function and proliferation. 
The correlation between GVHD and high affinity CMV-CTL may as well be of 
interest: Low and high affinity TCR recognize the same epitope but show to have different 
alloreactivity. More investigations could be relevant to improve the product for adoptive T-
cell therapy.  
In the line of paper III, more functional assays are necessary to understand the IL-
7/sIL-7R complex function and involvement in immune reconstitution. It could be interesting 
to analyze the STAT5 phosphorylation level and Bcl-2 expression of the T-cells over time 
upon IL-7 stimulation supplemented with different concentration of sIL-7R to better 
understand the soluble form of IL-7R mechanisms.  
Many parameters post-HSCT are important to consider for a clear interpretation of 
the correlation between immune response and clinical implications. Thus, some of the studies 
(paper II and III) are limited by the few number of patients or samples analyzed. Those 
findings would be interesting to reproduce in a different center and in a larger cohort of 
patients.  
Furthermore, post-HSCT the time-dependent analysis is essential to picture the cause-
consequence cascade of clinical events that occurs post-HSCT. The study I, II and III will 
need further investigation to get the best picture of this complicated network. In study I, the 
timing of CMV reactivation and GVHD needs to be analyzed with the quantification of viral-
specific IFNγ. In the study II, it is not possible to dissociate the cause and the consequence of 
low levels of sIL-7R or GVHD and other clinical events. In study III, the different classes of 
CMV-CTL need to be looked time-dependently of CMV reactivation and at closer time point 
around the clinical events. 
Last, longitudinal study of the immune response in patients with advanced cancer such as 
GBM and pancreatic cancer would enable the characterization of the evolution and 
parameters involved in the immune impairment of those patients. Blood samples before and 
after treatment or surgery, and at early versus late stage of cancer for immunomonitoring in 
parallel of pathogen monitoring may contribute to the understanding of the immune 
fitness/exhaustion of the patients and the pathogens such as CMV and EBV implication. 
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6 FRENCH POPULAR SCIENTIFIC SUMMARY 
 
A la question, "de quoi traite votre (ou cette) thèse ? la réponse est généralement adaptée en 
fonction de l’interlocuteur, mais pour simplifier, elle se réfère souvent à un programme télé 
éducatif et ludique de mon enfance : vous souvenez-vous de la série « Il était une fois ... la 
Vie" ? Cette thèse traite des personnages se déplaçant dans de petits vaisseaux qui défendent 
le corps humain contre les microbes (ceux qui avaient un gros nez): c'est de l’immunologie. 
 
Commençons donc par-là : les personnages se déplaçant dans de petits vaisseaux de « Il était 
une fois... la Vie » sont appelés communément globules blancs, et une population de ces 
globules est appelée lymphocytes. Il en existe beaucoup de genres mais les plus connus et sur 
lesquels cette thèse porte sont les lymphocytes T et B. Ils sont indispensables à la défense du 
corps humain contre les attaques venant de l’extérieur comme les virus, les bactéries mais 
aussi pour le protéger, les cellules qui dégénèrent pouvant être initiatrices de cancer. 
 
Les lymphocytes T et B participent à la défense immunitaire contre un virus, le 
Cytomégalovirus ou CMV. Ce virus est « inoffensif » pour les personnes saines au système 
immunitaire efficace. Dans le pire des cas, il provoque des symptômes comme ceux de la 
mononucléose, appelée aussi « maladie du baiser ». Il est tellement « inoffensif » que plus de 
90% de la population française adulte est porteuse de ce virus. « Inoffensif » est certainement 
inapproprié car il ne l’est pas vraiment: il est inoffensif uniquement parce que les défenses 
immunitaires de la majorité de la population sont efficaces contre ce virus. Le CMV 
provoque des déficiences comme la surdité et le retard mental chez le nouveau-né en cas 
d’infection chez la mère enceinte. Chez les personnes au système immunitaire déficient, le 
CMV peut se multiplier et avoir des répercussions graves comme la perte de la vision, 
l'inflammation du système digestif, la pneumonie et l'encéphalite pouvant même être fatal 
dans certains cas. Les principales personnes concernées et à surveiller sont donc celles 
porteuses du HIV et celles qui ont subi une transplantation d’organe ou de moelle osseuse. 
 
Dans les manuscrits I et IV, l'étude s'intéresse spécifiquement à la réponse des lymphocytes T 
contre le virus CMV chez les patients ayant subi une transplantation de moelle osseuse et 
ceux ayant eu un cancer du cerveau. La réponse immunitaire contre le virus reflète davantage 
l’efficacité générale des défenses immunitaires du patient plutôt que la réponse spécifique 
contre le virus. En pratique, si le système immunitaire du patient ne fonctionne pas 
efficacement, en général c'est que la réponse spécifique contre le CMV ne peut non plus être 
fonctionnelle. Les patients ayant une mauvaise réponse immunitaire ont un taux de survie 
plus faible que ceux ayant une réponse immunitaire fonctionnelle. Aussi, l'observation a mis 
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en évidence que la réponse immunitaire contre le CMV pouvait être diminuée par les 
traitements donnés aux patients pour traiter les inflammations ou le rejet de la greffe. De plus, 
à des stades avancés de cancer du cerveau (glioblastome), les patients se caractérisent par une 
faible réponse immunitaire contre le CMV. En conclusion, les traitements sembleraient donc 
être un facteur important dans l’augmentation des risques d’infection au CMV chez les 
patients transplantés. De plus la réponse immunitaire contre le CMV pourrait être un 
marqueur biologique permettant d'estimer l’évolution du cancer et la survie chez les patients 
atteints d’un cancer du cerveau. 
 
Le manuscrit II décrit plus en détail la réponse des lymphocytes T spécifiques contre le CMV 
chez les patients ayant subi une transplantation de moelle osseuse. Nous avons observé qu’il 
existe différentes classes de lymphocytes T en lien avec son affinité envers le virus CMV. 
Trois classes sont décrites : lymphocytes T à faible, moyenne et haute affinité. Il 
estintéressant de noter que ces trois classes présentent diffèrents signes de fatigue et 
d’activation ; celle à haute affinité semblant être plus actives que les autres classes. Lors de 
l’analyse faisant la corrélation avec les paramètres cliniques, l’élément important issu de 
l’étude est que les lymphocytes T à haute affinité envers le CMV sont trouvés en plus 
importante proportion chez les patients présentant des symptômes chroniques de la maladie 
du greffon contre l’hôte alors que l’inverse est relevé pour les lymphocytes T à affinité 
moyenne et faible. La maladie du greffon contre l’hôte est une grave complication d’une 
greffe de moelle osseuse, elle se produit quand les cellules provenant du donneur s’attaquent 
aux organes du patient. La forme chronique survient au-delà des trois mois suivant la 
transplantation. Les symptômes sont variés et contraignants pour le patient : douleurs 
musculaires, troubles pulmonaires etc. En conclusion, il est important d’étudier plus 
amplement les implications cliniques des différentes classes de lymphocytes T venant du 
donneur : les lymphocytes T avec une haute affinité envers le CMV seraient plus efficaces 
contre les infections et leur contrôle mais pourraient aussi engendrer un risque accru de 
développement d'une maladie chronique du greffon contre l’hôte. 
 
Le manuscrit III se focalise sur la production d’interleukine 7 (IL-7) et de son récepteur chez 
les patients ayant subi une transplantation de moelle osseuse. IL-7 est une cytokine, c’est à 
dire une molécule soluble qui agit à distance pour réguler les fonctions et activités de 
différentes cellules cibles. IL-7 intervient sur les lymphocytes : elle promeut la prolifération 
et la survie des lymphocytes T. Elle est donc nécessaire au système immunitaire et induit une 
meilleure défense contre les infections. Les cellules cibles sont sensibles à l’IL-7 car elles 
possèdent un récepteur spécifique à cette cytokine (IL-7R). Cependant, il existe aussi une 
forme soluble du récepteur, qui n’est donc pas attachée aux cellules. L’action de celle-ci (sIL-
7R) n’est pas encore bien connue. Le but de cette étude était de décrire la concentration de 
sIL-7R et IL-7 dans le sang de patients et de la corréler avec les paramètres cliniques. Il a 
donc été observé qu’une faible concentration de sIL-7R est liée au risque accru d’infection 
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par le CMV mais aussi au développement de la forme accrue de la maladie du greffon contre 
l’hôte. 
 
Cette thèse est donc assez large de par ses contextes cliniques. Le but était de mieux 
comprendre comment  l’humain se défend contre un virus aussi commun que dangereux 
selon l'état de santé de ce dernier. Après ces années d’études, force est de constater qu'il en 
ressort finalement plus de questions que de réponses: osons espérer malgré tout que cette 
contribution répond à certaines interrogations et aideront le corps medical ainsi que les 
patients.. 
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